Filed Nov 25, 2025Period of report Nov 24, 20250001213900-25-114990
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 24, 2025
Common StockF2F1
9,868
$3.44
$33.95K
60,602
Golden Arthur FDirector
4
Filed Nov 24, 2025Period of report Nov 21, 20250001213900-25-113841
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 21, 2025
Common StockF2F1
20,532
$2.87
$58.93K
50,734
Chaudhary ZuraizSee Remarks
4
Filed Nov 21, 2025Period of report Nov 20, 20250001213900-25-113723
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 21, 2025
Common Stock
1,000
$3.29
$3.29K
10,000
Direct
Chaudhary ZuraizSee Remarks
4
Filed Nov 17, 2025Period of report Nov 17, 20250001213900-25-111713
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 17, 2025
Common StockF1
2,500
$3.62
$9.05K
7,550
Direct
Chesed AbrahamBoard Observer
4
Filed Oct 29, 2025Period of report Oct 23, 20250001104659-25-103894
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 23, 2025
Common StockF1
14,286
$4.60
$65.72K
1,447,268
Indirect
Chaudhary ZuraizSee Remarks
4
Filed Oct 23, 2025Period of report Oct 23, 20250001104659-25-101924
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 23, 2025
Common Stock
5,050
$4.95
$25.00K
5,050
Direct
Golden Arthur FDirector
4
Filed Oct 23, 2025Period of report Oct 23, 20250001104659-25-101923
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 23, 2025
Common StockF1
20,202
$4.95
$100.00K
30,202
Direct
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
Direct
Filing footnotes · 2
F1Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.
F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.50, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F1Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.
F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.69, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F1Shares are held indirectly through ANC Merchant FLP and ANC Carlson FLP, each owned 48% by the reporting person, 48% by the reporting person's spouse, and 2% by each of the reporting person's two children; the reporting person disclaims beneficial ownership of the shares attributable to his spouse except to the extent of his pecuniary interest therein.
F1Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date.
